Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AMG 910 |
| Synonyms | |
| Therapy Description |
AMG 910 is a bispecific T-cell engager (BiTE) that targets CLDN18.2 expressed on tumor cells, and the CD3 antigen found on cytotoxic T cell lymphocytes, potentially resulting in T cell directed lysis of tumor cells (Ann Oncol. 2020 Sep 1;31(Supple. 4):S928-S929). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AMG 910 | AMG-910|AMG910|Bispecific Antibody AMG 910 | CLDN18.2 Antibody 23 | AMG 910 is a bispecific T-cell engager (BiTE) that targets CLDN18.2 expressed on tumor cells, and the CD3 antigen found on cytotoxic T cell lymphocytes, potentially resulting in T cell directed lysis of tumor cells (Ann Oncol. 2020 Sep 1;31(Supple. 4):S928-S929). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04260191 | Phase I | AMG 910 | Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma | Terminated | USA | NLD | FRA | ESP | DEU | AUT | 3 |